Adverse drug reactions to anti-tubercular drugs in HIV/TB co-infected patients

Research output: Contribution to journalArticle

Abstract

The medications used to treat HIV and TB can result in significant adverse effects and drug interactions which can adversely impact the disease management. The objective of this study is to determine the adverse reactions to anti-tubercular drugs in these HIV/TB co-infected patients. A retrospective study of case record files of HIV/TB co-infected patients on anti-tubercular treatment was carried out at a tertiary care teaching hospital and a district government hospital. Demographic details and adverse drug reactions were recorded. Data of 96 HIV/TB co-infected patients on anti-tubercular therapy was evaluated. Of these, 44 (45.8%)developed adverse drug reaction during the course of treatment. Rifampicin was considered to be responsible for 63.6% of adverse drug reactions. Hepatitis was the most common adverse reaction (31.8%). Almost half of the patient population with HIV/TB co-infection on anti-tubercular drugs experienced an adverse drug reaction. Early recognition and management of the adverse drug reactions is important to decrease morbidity and mortality.

Original languageEnglish
Pages (from-to)1934-1937
Number of pages4
JournalResearch Journal of Pharmaceutical, Biological and Chemical Sciences
Volume7
Issue number2
Publication statusPublished - 01-01-2016

Fingerprint

Drug-Related Side Effects and Adverse Reactions
HIV
Pharmaceutical Preparations
District Hospitals
Tertiary Healthcare
Rifampin
Disease Management
Drug interactions
Coinfection
Drug Interactions
Teaching Hospitals
Hepatitis
Therapeutics
Retrospective Studies
Demography
Morbidity
Teaching
Mortality
Population

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

@article{cf0b5d91cd5b4c1da2520594d30752d6,
title = "Adverse drug reactions to anti-tubercular drugs in HIV/TB co-infected patients",
abstract = "The medications used to treat HIV and TB can result in significant adverse effects and drug interactions which can adversely impact the disease management. The objective of this study is to determine the adverse reactions to anti-tubercular drugs in these HIV/TB co-infected patients. A retrospective study of case record files of HIV/TB co-infected patients on anti-tubercular treatment was carried out at a tertiary care teaching hospital and a district government hospital. Demographic details and adverse drug reactions were recorded. Data of 96 HIV/TB co-infected patients on anti-tubercular therapy was evaluated. Of these, 44 (45.8{\%})developed adverse drug reaction during the course of treatment. Rifampicin was considered to be responsible for 63.6{\%} of adverse drug reactions. Hepatitis was the most common adverse reaction (31.8{\%}). Almost half of the patient population with HIV/TB co-infection on anti-tubercular drugs experienced an adverse drug reaction. Early recognition and management of the adverse drug reactions is important to decrease morbidity and mortality.",
author = "Anshul Chatrath and Shenoy, {Ashok K.} and Ramapuram, {John T.} and Chowta, {Mukta N.} and Ashwin Kamath",
year = "2016",
month = "1",
day = "1",
language = "English",
volume = "7",
pages = "1934--1937",
journal = "Research Journal of Pharmaceutical, Biological and Chemical Sciences",
issn = "0975-8585",
publisher = "RJPBCS",
number = "2",

}

TY - JOUR

T1 - Adverse drug reactions to anti-tubercular drugs in HIV/TB co-infected patients

AU - Chatrath, Anshul

AU - Shenoy, Ashok K.

AU - Ramapuram, John T.

AU - Chowta, Mukta N.

AU - Kamath, Ashwin

PY - 2016/1/1

Y1 - 2016/1/1

N2 - The medications used to treat HIV and TB can result in significant adverse effects and drug interactions which can adversely impact the disease management. The objective of this study is to determine the adverse reactions to anti-tubercular drugs in these HIV/TB co-infected patients. A retrospective study of case record files of HIV/TB co-infected patients on anti-tubercular treatment was carried out at a tertiary care teaching hospital and a district government hospital. Demographic details and adverse drug reactions were recorded. Data of 96 HIV/TB co-infected patients on anti-tubercular therapy was evaluated. Of these, 44 (45.8%)developed adverse drug reaction during the course of treatment. Rifampicin was considered to be responsible for 63.6% of adverse drug reactions. Hepatitis was the most common adverse reaction (31.8%). Almost half of the patient population with HIV/TB co-infection on anti-tubercular drugs experienced an adverse drug reaction. Early recognition and management of the adverse drug reactions is important to decrease morbidity and mortality.

AB - The medications used to treat HIV and TB can result in significant adverse effects and drug interactions which can adversely impact the disease management. The objective of this study is to determine the adverse reactions to anti-tubercular drugs in these HIV/TB co-infected patients. A retrospective study of case record files of HIV/TB co-infected patients on anti-tubercular treatment was carried out at a tertiary care teaching hospital and a district government hospital. Demographic details and adverse drug reactions were recorded. Data of 96 HIV/TB co-infected patients on anti-tubercular therapy was evaluated. Of these, 44 (45.8%)developed adverse drug reaction during the course of treatment. Rifampicin was considered to be responsible for 63.6% of adverse drug reactions. Hepatitis was the most common adverse reaction (31.8%). Almost half of the patient population with HIV/TB co-infection on anti-tubercular drugs experienced an adverse drug reaction. Early recognition and management of the adverse drug reactions is important to decrease morbidity and mortality.

UR - http://www.scopus.com/inward/record.url?scp=84962513392&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962513392&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 1934

EP - 1937

JO - Research Journal of Pharmaceutical, Biological and Chemical Sciences

JF - Research Journal of Pharmaceutical, Biological and Chemical Sciences

SN - 0975-8585

IS - 2

ER -